INmune Bio (NASDAQ:INMB) Posts Earnings Results

INmune Bio (NASDAQ:INMB) issued its quarterly earnings data on Thursday. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.14, Zacks reports.

INmune Bio Price Performance

Shares of INMB traded down $0.27 during mid-day trading on Friday, reaching $7.14. 61,057 shares of the company’s stock were exchanged, compared to its average volume of 241,182. The stock has a market capitalization of $189.86 million, a PE ratio of -3.25 and a beta of 1.93. The business’s fifty day simple moving average is $8.39 and its 200-day simple moving average is $6.37. INmune Bio has a 52-week low of $4.32 and a 52-week high of $12.72.

Analyst Upgrades and Downgrades

Several research firms have weighed in on INMB. Maxim Group lifted their target price on INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Scotiabank increased their target price on INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a report on Tuesday, February 11th. RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on INmune Bio in a research note on Tuesday, January 28th. They set a “buy” rating and a $23.00 target price for the company. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.